Panacea Financial v. Tallied Technologies, Inc.

Background

Panacea alleged that it shared confidential information with Tallied under a Mutual Non-Disclosure Agreement while the companies discussed working together on a credit-card program involving the American Dental Association. The alleged information included the timing and expected features of the American Dental Association’s request for proposals, its preferences, Panacea’s proposed program structure, and Panacea’s pricing and funding information.

Panacea alleged that Tallied later submitted its own proposal, used Panacea’s confidential pricing information to undercut Panacea, and won the request-for-proposals process. Panacea asserted claims for breach of contract, unjust enrichment, violation of the Delaware Uniform Trade Secrets Act, common-law misappropriation or conversion of confidential information, tortious interference with prospective business relationships, and unfair competition.

Trade-secret claim

The court denied Tallied’s motion to dismiss the Delaware Uniform Trade Secrets Act claim. At the motion-to-dismiss stage, the court found that Panacea plausibly alleged the existence of trade secrets. The alleged information was described with enough detail about its context, timing, importance, and type to distinguish it from general categories of potentially protectable information. The court also found that Panacea plausibly alleged that the information had economic value because it was not generally known and that Panacea had taken reasonable steps to keep it secret.

The court further found that Panacea plausibly alleged misappropriation. The complaint alleged that Tallied treated Panacea as a partner while secretly preparing its own proposal, lacked prior experience with large business-card programs, and suddenly submitted a highly competitive revenue-share proposal after receiving Panacea’s confidential pricing information. The court held that these allegations were sufficient at the pleading stage.

Preemption of other state-law claims

Tallied argued that Panacea’s unjust-enrichment, unfair-competition, tortious-interference, and common-law misappropriation claims were displaced, or preempted, by the Delaware Uniform Trade Secrets Act. The court granted Tallied’s motion to dismiss Panacea’s unjust-enrichment and common-law misappropriation claims because they were based on the same alleged use of Panacea’s confidential information as the trade-secret claim.

The court denied the motion to dismiss the unfair-competition and tortious-interference claims on preemption grounds. It found that Panacea alleged separate facts supporting those claims, including that Tallied allegedly pretended to pursue a partnership with Panacea to obtain confidential information and then used improper means to interfere with Panacea’s expected business relationship with the American Dental Association.

Breach-of-contract claim

The court denied Tallied’s motion to dismiss Panacea’s breach-of-contract claim. Tallied argued that the American Dental Association request for proposals was not covered by the nondisclosure agreement because Tallied may have learned about it independently. The court explained that this argument did not defeat the allegation that Panacea’s pricing strategy and the American Dental Association’s private preferences remained confidential. The court also rejected Tallied’s argument that Panacea’s allegations about use of its information were speculative, for the same reasons supporting the trade-secret claim.

Disposition

The court granted Tallied’s motion to dismiss in part and denied it in part. Panacea’s unjust-enrichment and common-law misappropriation or conversion claims were denied with leave to amend. The court denied the remainder of Tallied’s motion. Panacea may file an amended complaint within 21 days, solely to cure the deficiencies identified in the order. The court also continued the case-management conference from October 7, 2025, to December 2, 2025, at 2:00 p.m.